Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: Results of the randomized AZABACHE Spanish trial

  • García-Sanz, R.
  • Oriol, A.
  • Moreno, M.J.
  • Rubia, De La
  • Payer, A.R.
  • Hernández, M.T.
  • Palomera, L.
  • Teruel, A.I.
  • Blanchard, M.J.
  • Gironella, M.
  • Ribas, P.
  • Bargay, J.
  • Abellá, E.
  • Granell, M.
  • Ocio, E.M.
  • Ribera, J.M.
  • San Miguel, J.F.
  • Mateos, M.V.
This study analyzed the anti-myeloma effect of zoledronic acid monotherapy by investigating patients at the time of asymptomatic biochemical relapse. One hundred patients were randomized to receive either zoledronic acid (4 mg iv/4 weeks, 12 doses) (n=51) or not (n=49). Experimental and control groups were well balanced for disease and prognostic features. Zoledronic acid did not show an antitumor effect according to changes in M-component. However, there were fewer symptomatic progressions in the experimental group than in the control group (34 ver- sus 41, respectively; P=0.05) resulting in a median time to symptoms of 16 versus 10 months (P=0.161). The median time to next therapy was also slightly longer for the treated group than the untreated, control group (13.4 versus 10.1 months), although the difference was not statistically significant (P=0.360). The pattern of relapses was dif- ferent for treated versus control patients: progressive bone disease (8 versus 20), anemia (24 versus 18), renal dysfunc- tion (1 versus 2), and plasmacytomas (1 versus 1, respectively). This concurred with fewer skeletal-related events in the treated group than in the control group (2 versus 14), with a projected 4-year event proportion of 6% versus 40% (P<0.001). In summary, zoledronic acid monotherapy does not show an antitumor effect on biochemical relapses in multiple myeloma, but does reduce the risk of progression with symptomatic bone disease and skeletal compli- cations. This trial was registered in the ClinicalTrials.gov database with code NCT01087008
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma, impact of an MGUS-like signature

  • Rodriguez-Otero, Paula|||0000-0001-5236-7785
  • Mateos, M. V.|||0000-0003-2390-1218
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Hernández, Miguel Teodoro|||0000-0002-6576-7881
  • Ocio, Enrique M.|||0000-0002-5765-0085
  • Rosiñol, Laura|||0000-0002-2534-9239
  • Martínez Martínez, Rafael
  • Teruel, Ana Isabel|||0000-0003-1559-7607
  • Gutierrez, Norma|||0000-0001-5834-9510
  • Bargay, Joan|||0000-0002-6739-3916
  • Bengoechea, Enrique
  • González, Yolanda
  • Perez de Oteyza, Jaime|||0000-0002-8338-2037
  • Gironella, Mercedes|||0000-0002-8106-8909
  • Nuñez-Córdoba, Jorge
  • Encinas, Cristina|||0000-0002-9001-9754
  • Martín Sánchez, Jesús|||0000-0003-4250-4824
  • Cabrera-Lopez, Carlos|||0000-0002-6251-4854
  • Palomera, Luis|||0000-0003-0359-7191
  • De Arriba, Felipe|||0000-0002-4451-1318
  • Cedena, María Teresa|||0000-0001-5851-3720
  • Puig, Noemí|||0000-0001-7535-3861
  • Oriol, Albert|||0000-0001-6804-2221
  • Paiva, Bruno|||0000-0003-1977-3815
  • Bladé Creixenti, Juan|||0000-0002-4563-3405
  • Lahuerta, J. J.|||0000-0002-3393-9570
  • San Miguel, Jesús F.
Disease control at 5 years would be a desirable endpoint for elderly multiple myeloma (MM) patients, but biomarkers predicting this are not defined. Therefore, to gain further insights in this endpoint, a population of 498 newly diagnosed transplant-ineligible patients enrolled in two Spanish trials (GEM2005MAS65 and GEM2010MAS65), has been analyzed. Among the 435 patients included in this post-hoc study, 18.6% remained alive and progression free after 5 years of treatment initiation. In these patients, overall survival (OS) rate at 10 years was 60.8% as compared with 11.8% for those progressing within the first 5 years. Hemoglobin (Hb) ≥ 12 g/dl (OR 2.74, p = 0.001) and MGUS-like profile (OR 4.18, p = 0.005) were the two baseline variables associated with long-term disease-free survival. Upon including depth of response (and MRD), Hb ≥ 12 g/dl (OR 2.27) and MGUS-like signature (OR 7.48) retained their predictive value along with MRD negativity (OR 5.18). This study shows that despite the use of novel agents, the probability of disease control at 5 years is still restricted to a small fraction (18.6%) of elderly MM patients. Since this endpoint is associated with higher rates of OS, this study provides important information about diagnostic and post-treatment biomarkers helpful in predicting the likelihood of disease control at 5 years.